In this latest installment of VC playbook, In Vivo speaks to Naveed Siddiqi, senior partner at Novo Ventures. He discusses the group’s strategy, the European investment outlook for life sciences and how COVID-19 has permanently shifted perceptions of the biopharma industry.

Tempest goes public via a reverse merger with Millendo. Takeda inks its ninth deal of 2021, a discovery pact with BridGene around its chemoproteomics technology.

After a decade of research, the Spanish biotech believes its lead candidate BO-112 can turn ‘cold’ tumors ‘hot,' offering the potential to rescue patients who are resistant to current checkpoint inhibitor therapy.

After disappointment in sickle cell anemia, Modus Therapeutics will now develop its lead asset sevuparin as a treatment for sepsis and septic shock and plans a public listing in Sweden to fund the new strategy, its CEO tells Scrip.